Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)

September 2018: Independent professional body guideline

Asthma (update)

September 2018: NICE Quality Standard

Depression in adults (update)

September 2018: NICE Quality Standard

Eating disorders

September 2018: NICE Quality Standard

Ovarian cancer (refresh)

September 2018: SIGN guidance

Renal replacement therapy

October 2018: NICE Clinical Guideline

Decision making and mental capacity

October 2018: NICE Social Care Guidance

Foetal alcohol spectrum disorder (update)

October 2018: SIGN guidance

Abdominal aortic aneurysm: diagnosis and management

November 2018: NICE Clinical Guideline

Contraceptive choices for women who are obese/overweight

November 2018: Independent professional body guideline

Visit the Guidelines website

NICE gives Lilly’s Verzenios chance to compete with rivals

NICE gives Lilly’s Verzenios chance to compete with rivals 17 Jan 2019
Ibrance and Verzenios gained NICE approval in November 2017, which means Lilly has some catching up to do. ... Baroness Delyth Morgan, chief executive at Breast Cancer Now (pictured) welcomed NICE’s decision.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig 9 Jan 2019
Aimovig has a list price of around £5, 000 per year, although Novartis has offered NICE a confidential discount. ... Ahmad confirmed that the company would continue to work with NICE to secure access for those with chronic migraines.

AstraZeneca wins NICE backing for asthma injection

AstraZeneca wins NICE backing for asthma injection 4 Jan 2019
inhalers. It’s a relatively uncommon  form of asthma, and according to NICE it affects around 100, 000 people in the UK. ... It has an original list price of £1, 955 per dose, but as always the discount offered to NICE remains confidential.

NICE appraisal fees to be introduced despite opposition

NICE appraisal fees to be introduced despite opposition 14 Dec 2018
Concessions made for small companies. England’s cost effectiveness watchdog NICE is to start charging pharmaceutical companies for appraisals of their drugs from April 2019, despite considerable resistance from the industry ... The new charges are

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done 14 Dec 2018
Room for manoeuvre after initial rejection. NICE has issued draft guidance not recommending two new rival treatments for the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR) – Alnylam’s Onpattro and ... Gaining NICE

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Infographics